Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clemastine and Aerobic Exercise for Cognitive Dysfunction in Schizophrenia
NCT06315972Phase 2Not yet recruiting
- Sponsor
- LMU Klinikum
- Start
- Apr 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of clemastine in schizophrenia, sponsored by LMU Klinikum. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
clemastine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06315972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06315972.